NASDAQ:TARS Tarsus Pharmaceuticals Q2 2023 Earnings Report $41.55 +0.97 (+2.39%) Closing price 04:00 PM EasternExtended Trading$41.72 +0.17 (+0.42%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Tarsus Pharmaceuticals EPS ResultsActual EPS-$1.17Consensus EPS -$1.08Beat/MissMissed by -$0.09One Year Ago EPSN/ATarsus Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATarsus Pharmaceuticals Announcement DetailsQuarterQ2 2023Date8/10/2023TimeN/AConference Call DateThursday, August 10, 2023Conference Call Time7:00AM ETUpcoming EarningsTarsus Pharmaceuticals' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Tarsus Pharmaceuticals Earnings HeadlinesWilliam Blair Has Bearish Estimate for TARS FY2026 EarningsJuly 16 at 2:01 AM | americanbankingnews.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $66.67 Consensus PT from AnalystsJuly 15 at 2:17 AM | americanbankingnews.comBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist believed — until he found a little-known $15 gold ETF that’s now paying up to 64% annually in monthly cash. No mining stocks. No futures. Just steady income from an asset that used to pay nothing.July 16 at 2:00 AM | Investors Alley (Ad)Tarsus Pharmaceuticals Stock Price, Quotes and ForecastsJuly 13 at 10:38 PM | benzinga.comTarsus Pharmaceuticals Inc Ordinary Shares - MorningstarJuly 2, 2025 | morningstar.comMTarsus Pharmaceuticals Becomes Oversold (TARS)June 19, 2025 | nasdaq.comSee More Tarsus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tarsus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tarsus Pharmaceuticals and other key companies, straight to your email. Email Address About Tarsus PharmaceuticalsTarsus Pharmaceuticals (NASDAQ:TARS), founded in 2016 and headquartered in Westlake Village, California, is a clinical‐stage biopharmaceutical company dedicated to developing novel therapies for eye diseases. The company’s research and development efforts concentrate on small‐molecule treatments designed to address unmet needs in the anterior segment of the eye, including inflammatory, infectious and degenerative conditions. The company’s lead investigational product, lotilaner ophthalmic solution (TP-03), is being evaluated for the treatment of Demodex blepharitis, a common but often underdiagnosed eyelid disorder. Tarsus also has a pipeline of additional candidates, including TP-01, a kinase inhibitor for post-surgical ocular pain and inflammation, and TP-04, which targets meibomian gland dysfunction in dry eye disease. These programs leverage proprietary mechanisms of action aimed at providing more effective and convenient treatment options than currently available therapies. While Tarsus initially focuses its clinical and commercial efforts on the U.S. market, the company has plans to pursue regulatory submissions in Europe and other international regions. Its global strategy includes partnerships with leading ophthalmology centers and contract research organizations to advance late-stage trials. The leadership team is headed by President and Chief Executive Officer F. West Sisselman, whose more than 25 years of biopharmaceutical experience are complemented by executives with deep expertise in clinical development, regulatory affairs and commercialization.Written by Jeffrey Neal JohnsonView Tarsus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still Strong Upcoming Earnings Cintas (7/17/2025)Interactive Brokers Group (7/17/2025)Netflix (7/17/2025)PepsiCo (7/17/2025)Abbott Laboratories (7/17/2025)Elevance Health (7/17/2025)GE Aerospace (7/17/2025)American Noble Gas (7/17/2025)Marsh & McLennan Companies (7/17/2025)Novartis (7/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
